Burtness, B., Rosenberg, A. J., Swiecicki, P. L., Geiger, J. L., Oliva, M., Lyu, X., Curtin, J. C., Toyoizumi, K., Xie, J., Wade, M., Diorio, B., Kapoor, A., Yilmaz, E., Baig, M., Kim, P., Verheijen, R. B., Shah, S., Harrington, K. J., Abdeddaim, C., Adkins, D., Ahn, M., Bhatia, A., BraƱa, I., Calderon, B., Forster, M., Geiger, J., Guo, Y., Hahn, D., Haigentz, M., Harrington, K., Iglesias, L., Ince, W., ji, D., Kadowaki, S., Kawecki, A., Keam, B., Kerrigan, K., Kim, S., Li, S., Lim, S. M., Lin, J., Liu, L., McDermott, J., Metcalf, R., Pawlowska, E., Rosenberg, A., Rutkowski, T., Sandhu, M., Shariff, N. M., Sheth, S., Spira, A., Sukari, A., Swiecicki, P. L., Tanaka, H., Viala, C., Vidales, Z., Wang, H., Yang, M., Yang, K. (2026). Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01042